| Dr Joseph Paul Alukal, MD | |
|
150 E 32nd St, 2nd Floor, New York, NY 10016-6024 | |
| (646) 825-6300 | |
| (646) 825-6399 |
| Full Name | Dr Joseph Paul Alukal |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Experience | 23 Years |
| Location | 150 E 32nd St, New York, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003084203 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 248400 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| New York-presbyterian Hospital | New york, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Trustees Of Columbia University In The City Of New York | 8527972546 | 1895 |
News Archive
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
Obesity is taking a hefty toll on the health of children and young adults, leaving more Americans facing the burden of a lifetime of diabetes care and management.
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
› Verified 1 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20081202000185 |
News Archive
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
Obesity is taking a hefty toll on the health of children and young adults, leaving more Americans facing the burden of a lifetime of diabetes care and management.
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
› Verified 1 days ago
| Entity Name | New York University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1285826438 PECOS PAC ID: 1355232422 Enrollment ID: O20090822000026 |
News Archive
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
Obesity is taking a hefty toll on the health of children and young adults, leaving more Americans facing the burden of a lifetime of diabetes care and management.
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
› Verified 1 days ago
| Entity Name | Trustees Of Columbia University In The City Of New York |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1508266347 PECOS PAC ID: 8527972546 Enrollment ID: O20151201002613 |
News Archive
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
Obesity is taking a hefty toll on the health of children and young adults, leaving more Americans facing the burden of a lifetime of diabetes care and management.
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Joseph Paul Alukal, MD 1233 York Ave, Apartment 10n, New York, NY 10065-6306 Ph: (617) 290-3263 | Dr Joseph Paul Alukal, MD 150 E 32nd St, 2nd Floor, New York, NY 10016-6024 Ph: (646) 825-6300 |
News Archive
The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 94 national research and training grants totaling $46,633,000 to 70 institutions nationwide in the first of two grants cycles for 2011.
Progenics Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA), along with the European Medicines Agency (EMA) of the European Union (E.U.) and Health Canada, the Canadian Regulatory Agency, have each approved single-use, pre-filled syringes of RELISTOR® (methylnaltrexone bromide) Subcutaneous Injection for use in their respective territories. These pre-filled syringes provide a simplified dosing option for the treatment of opioid-induced constipation (OIC) in palliative-care patients with advanced illness.
Obesity is taking a hefty toll on the health of children and young adults, leaving more Americans facing the burden of a lifetime of diabetes care and management.
A toxin linked to a targeted monoclonal antibody has shown "compelling" antitumor activity in patients with non-Hodgkin lymphomas who were no longer responding to treatment, according to a report from Dana-Farber Cancer Institute.
› Verified 1 days ago
Dr. Reza Mehrazin, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 1 Gustave L Levy Pl # 1272, Mount Sinai School Of Medicine / Urology Dept, New York, NY 10029 Phone: 212-241-4812 Fax: 212-987-4675 | |
Dr. Lamont Jordan Barlow, Urology Medicare: Medicare Enrolled Practice Location: 423 E 23rd St, New York, NY 10010 Phone: 212-686-7500 | |
Matthew Katz, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 222 E 41st St, New York, NY 10017 Phone: 646-825-6300 | |
Dr. Victor Allon Mcpherson, MD, MSC Urology Medicare: Not Enrolled in Medicare Practice Location: 1275 York Ave, New York, NY 10065 Phone: 551-444-8672 | |
Mark Thomas Dawidek, Urology Medicare: Not Enrolled in Medicare Practice Location: 303 E 60th St Apt 32g, New York, NY 10022 Phone: 236-989-9955 | |
David M Weiner, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 161 Fort Washington Ave, 11th Floor, New York, NY 10032 Phone: 212-305-0114 Fax: 212-305-0129 |